MIRA Pharmaceuticals, Inc. Erez Aminov, CEO

MIRA is developing a new

molecular synthetic THC analog called MIRA1a, designed for the treatment of

adult patients with anxiety and cognitive decline, typically associated with

early-stage dementia.

 

MIRA’s initial focus will

be a dual path: potentially winning in traditional pain and anxiety markets as

well as the marijuana analog markets with a potentially safe and effective option if approved

by the FDA.